Evidence map›Paper›PMID 40900155›Full record

ReviewJournal of molecular medicine (Berlin, Germany)2025

Application of mesenchymal stem cells in ferroptosis-related diseases.

Xianmei Zhong, Xue Zhang, Yuxuan Zhu, Xi Zheng

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xianmei ZhongDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.
Xue ZhangDepartment of Pharmacy, Weiyuan People's Hospital, Weiyuan 642450, Sichuan, China.
Yuxuan ZhuDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China. zhuyuxuan6688@163.com.
Xi ZhengDepartment of Pharmacy, Personalized Drug Research and Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China. zhengxi198668@163.com.ORCID 0009-0000-8262-9221

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modern medicine has achieved groundbreaking advancements in disease diagnosis and treatment, yet significant challenges remain in managing conditions such as age-related diseases, tumors, autoimmune disorders, and neurological conditions. Conventional drug therapies often suffer from inadequate targeting, severe toxic side effects, and limited therapeutic efficacy, leading to adverse clinical outcomes such as disease recurrence and organ dysfunction. In recent years, mesenchymal stem cells (MSCs) have demonstrated transformative potential in regenerative medicine and disease therapy. Leveraging their multipotent differentiation potential, immunomodulatory properties, and paracrine functions, MSCs offer innovative strategies by enhancing tissue repair and microenvironmental homeostasis. Notably, ferroptosis-a newly identified form of regulated cell death-has emerged as a critical research frontier. MSCs and their exosomes exhibit a remarkable ability to modulate ferroptosis by regulating iron ions and lipid peroxide levels. This review provides an in-depth analysis of the molecular pathways through which MSCs influence ferroptosis. Additionally, it explores recent advances in ferroptosis regulation in transplanted MSCs, shedding light on their clinical applicability. In summary, this work underscores the therapeutic promise of MSCs in treating ferroptosis-associated diseases.

Indexed as

FerroptosisMesenchymal Stem CellsMesenchymal Stem Cell TransplantationAnimalsHumansDiseasesFerroptosisMesenchymal stem cells

Identifiers

PMID40900155

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.